Scientists Discover New Health Benefit of Metformin Beyond Diabetes

For many years, metformin has been the primary medication prescribed for managing type 2 diabetes. Millions of individuals take it daily to control blood sugar levels and decrease the chance of diabetes-related complications.

Recently, researchers suggest this widely used drug might have another unexpected benefit: a potential association with a reduced risk of prostate cancer in men.

Researchers from the University of Otago examined a decade’s worth of scientific evidence to better understand the long-term health effects of metformin. Their extensive review included studies involving approximately 2.25 million people with type 2 diabetes, making it one of the most comprehensive analyses of its kind.

Type 2 diabetes is a persistent condition where the body cannot effectively utilize insulin. Elevated blood sugar over time increases the risk of heart disease, strokes, kidney failure, blindness, and nerve damage. Metformin primarily lowers blood sugar by decreasing liver sugar production and enhancing insulin sensitivity.

Previous studies have indicated that individuals taking metformin often experience lower rates of cardiovascular disease and may live longer than expected. Some research also hints at benefits related to brain health. The new review corroborates these findings, noting reductions in cardiovascular issues, dementia, and overall mortality among metformin users.

A particularly noteworthy discovery involved prostate cancer. The data indicated that men with type 2 diabetes using metformin appear less prone to developing this prevalent cancer. Although earlier research explored whether metformin might diminish risks for various types of cancer, evidence specifically linked to prostate cancer has been limited.

Prostate cancer ranks as the second most common cancer diagnosed in men globally. Early detection often leads to successful treatment, but managing advanced stages can be challenging. As men age, the risk of prostate cancer increases, making prevention a growing concern as populations age worldwide.

Senior researcher Associate Professor Yoram Barak expressed enthusiasm about these findings, suggesting that metformin could have broader health benefits than previously understood.

However, he cautioned that individuals without diabetes should not start taking metformin solely to lower cancer risk. More robust evidence is needed before such practices can be recommended.

The researchers also emphasized the importance of studying healthy aging. Advances in medicine are enabling people to live longer, yet many older adults spend their later years battling chronic diseases. Investigating whether existing medications can slow the aging process or prevent age-related illnesses could greatly enhance quality of life and reduce healthcare costs.

There are notable limitations to this research. Since it relies on previously published studies, it can only identify associations rather than establish a cause-and-effect relationship.

Variations in diet, physical activity, smoking habits, healthcare access, and other medications might partly explain the observed lower cancer rates. To determine whether metformin directly protects against prostate cancer, randomized clinical trials are necessary.

Despite these constraints, the review adds to the growing evidence that metformin might provide health advantages beyond blood sugar control. Future studies will clarify whether its effects on aging and cancer risk are real and applicable to individuals without diabetes.

If you’re interested in diabetes-related topics, consider reviewing studies about bananas and blood sugar, or how honey might help regulate blood glucose levels.

For more health insights, explore recent research on vitamin D, which could reduce dangerous complications in diabetes, and plant-based proteins that may help reverse type 2 diabetes.

The study was published in the journal Rejuvenation Research.

Source: University of Otago.